Login to Your Account


Odonate prices, raises $150M, as Denali upsizes IPO

By Marie Powers
News Editor

Thursday, December 7, 2017

Chemotherapeutic developer Odonate Therapeutics Inc. extended the 2017 biopharma IPO window, offering 6.25 million common shares at $24 apiece to raise $150 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription


»

For Sales Inquiries,
http://clarivate.com/life-sciences/news/bioworld/#

 
Privacy Policy | Terms of Use | Copyright
 
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Clarivate Analytics